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EDITORIALTargeting CCL2/CCR2 in Tumor-Infiltrating Macrophages: A Tool
Emerging Out of the Box Against Hepatocellular Carcinomaepatocellular carcinoma (HCC) is the most frequentHprimary liver tumor and a leading cause of cancer-
related mortality. Unfortunately, the majority of HCC pa-
tients present with advanced disease, when locoregional
curative strategies are no longer applicable. On the other
hand, early, HCCs proved to be resistant to conventional
chemotherapies, and drugs targeting specific growth factor
signaling pathways tested over the past decade have not
succeeded in clinical trials. The molecular heterogeneity of
HCCs and the lack of biomarker-based patient stratification
strategies may underlie the failure of most of these trials.
HCCs usually develop on a background of chronic liver
injury and regeneration, inflammation, and fibrosis, features
that promote tumor hypervascularity, the other histologic
hallmark of this neoplasia. Indeed, the fibrotic and immune
microenvironment plays a key role in pathogenic angio-
genesis and HCC development and progression. This tenet is
supported not only by experimental evidence, but also by
the fact that the only therapeutic agents showing clinical
efficacy in advanced HCC are those directed toward the
interaction of HCC with its microenvironment (ie, anti-
angiogenic multikinase inhibitors such as sorafenib, and
immune checkpoint inhibitors such as antibodies targeting
programmed cell death receptor 1 and its ligand).1 These
observations attest to the potential of targeting the tumor
pro-angiogenic and immune milieu for the development of
effective anti-HCC therapies. Within the tumor microenvi-
ronment, an increased presence of tumor-associated mac-
rophages (TAMs) has been associated consistently with
poor patient prognosis. Chemokines play a fundamental role
in monocyte recruitment and their maturation into TAMs,
cells that have been linked mechanistically to fibrogenesis
and angiogenesis development during chronic liver injury
and hepatocarcinogenesis.2,3 Among the broad family of
chemokines, CCL2 (also known as MCP-1) is secreted by
most liver cells upon stress and injury, and its only known
receptor, CCR2, is expressed in monocytes and liver mac-
rophages. Recent experimental studies have shown that
CCL2/CCR2 signaling promotes liver inflammation, fibrosis,
and pathologic angiogenesis. Moreover, enhanced CCL2
levels have been linked to a decreased survival rate in HCC
patients. Importantly, targeting of CCL2/CCR2 signaling
using either small-molecule antagonists, neutralizing anti-
bodies, or RNA aptamer-based inhibitors quells the pro-
gression of pathogenic angiogenesis and the growth of
subcutaneous HCC xenografts and endogenous liver
tumors.2–5 Together, these findings lend support to the
potential application of CCL2/CCR2 and TAM targeting
strategies in HCC prevention and treatment. Nevertheless, inCelluview of the complex role played by macrophages in chronic
liver injury and carcinogenesis, including protumoral and
antitumoral functions, a detailed understanding of the
function of TAMs in this context is warranted.
The study by Bartneck et al6 aimed to dissect the TAM
subtypes involved in HCC progression, with a particular focus
on the role of TAMs mobilized by CCL2/CCR2 signaling in
fibrogenesis-driven hepatocarcinogenesis. Interestingly, in
resected human HCCs the investigators found a specific
accumulation of CCR2þ TAMs at the stroma/tumor interface,
co-localizing with endothelial cells in areas of intense
vascularization. These TAMs did not belong to the suppressive
M2-like population, but to an M1 population showing an in-
flammatory and pro-angiogenic polarization. To grasp the
pathogenic significance of CCR2þ TAMs in angiogenesis and
tumor development, Bartneck et al6 applied an RNA aptamer
CCL2 inhibitor (CCL2i) in a relevant mouse model of liver
fibrosis and hepatocarcinogenesis (diethylnitrosamine plus
CCl4 administration). CCL2 inhibition resulted in reduced
TAM1 liver infiltrate and pathogenic angiogenesis, a certain
improvement of tissue fibrosis, and a significant inhibition of
tumor progression. These findings confirmed the anti-HCC
potential of CCL2/CCR2 inhibition observed in previous
studies using less clinically meaningful HCC models and
highlight the strong impact of CCR2 targeting on tumor-
associated angiogenesis. Previous studies in different types
of tumors found that M2-polarized TAMs have higher angio-
genic potential than the TAM1 population. This is at variance
with the observations of Bartneck et al,6 who found that TAM
co-localizing with newly formed vessels in the chronically
injured liver were of the TAM1 type and, most interestingly,
that this TAM1 population expressed much higher levels of
CCR2. As the investigators discussed, angiogenesis inhibition
may indeed be a key aspect of the antitumoral activity of
CCL2i. However, the underlying mechanisms, including the
observed effects of CCL2i on both TAM1 and TAM2 pop-
ulations, and the molecular mechanisms of TAM-mediated
angiogenesis, still remain to be fully elucidated. The study
by Bartneck et al6 further supports the notion that CCL2 tar-
geting could be a new strategy against HCC amenable for
combination with other efficacious agents such as multikinase
and immune checkpoint inhibitors. In fact, CCL2/CCR2
signaling inhibitors are currently being clinically tested for the
treatment of nonalcoholic steatohepatitis and liver fibrosis,
conditions strongly linked to HCC development.5 Interference
with CCL2/CCR2 signaling certainly may be effective for the
inhibition of established HCC progression. However, given the
key role played by the immune system, including macro-
phages, in cancer surveillance, the application of this strategylar and Molecular Gastroenterology and Hepatology 2019;7:293–294
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monitoring.
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